Abdominal Neoplasms - 350 Studies Found
| Active, not recruiting |
: Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients : Ovarian, Fallopian Tube, and Primary Peritoneal Cancer : 2012-03-30 : Drug: Metformin Patients receiving primary surgical debulk |
| Completed |
: Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission :
: Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21 The injection wil |
| Withdrawn |
: Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC :
: 2010-07-14 : Device: Echocardiogram Echocardiography will be utilized during the procedure to guide fluid management. |
| Terminated |
: Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer :
: 2009-05-09 :
|
| Active, not recruiting |
: Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity :
|
| Completed |
: A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer :
: 2008-05-19 : Biological: DCVac-L Subjects will receive three doses of intradermal vaccination with ~5-10 x 106 dendri |
| Completed |
: Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers : Peritoneal Neoplasms : 2008-04-23 : Drug: nanoparticulate paclitaxel This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patien |
| Completed |
: Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer :
: 2007-06-19 :
|
| Completed |
: A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer :
: 2007-04-16 : Drug: pemetrexed 900 mg/m2, intravenous (IV), every 21 days, until disease progression |
| Completed |
: Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin :
: 2007-02-15 :
|